Short Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Declines By 6.0%

Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 10,140,000 shares, a decrease of 6.0% from the October 15th total of 10,790,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 7.6 days.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in Aquestive Therapeutics in the 3rd quarter valued at $28,000. Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at about $27,000. SG Americas Securities LLC bought a new stake in Aquestive Therapeutics during the first quarter worth about $54,000. Harvey Capital Management Inc. acquired a new position in Aquestive Therapeutics during the third quarter valued at approximately $88,000. Finally, Intech Investment Management LLC bought a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $90,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $4.64 on Tuesday. Aquestive Therapeutics has a one year low of $1.73 and a one year high of $6.23. The firm has a market cap of $423.07 million, a P/E ratio of -9.80 and a beta of 2.82. The stock’s 50-day moving average is $4.99 and its 200-day moving average is $3.88.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the firm posted ($0.03) EPS. Equities analysts anticipate that Aquestive Therapeutics will post -0.47 EPS for the current year.

Analyst Upgrades and Downgrades

AQST has been the topic of several recent research reports. Leerink Partners raised their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Aquestive Therapeutics currently has an average rating of “Buy” and a consensus target price of $9.80.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.